![](https://webarchive.library.unt.edu/eot2008/20090509235542im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20090509235542im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20090509235542im_/http://www.cancer.gov/images/spacer.gif) |
![------](https://webarchive.library.unt.edu/eot2008/20090509235542im_/http://www.cancer.gov/images/spacer_darkblue.gif) VOLUME 2, ISSUE 2
|
Proteomics: Research for the 21st Century
Reported by NCI Press Office Staff
February 7, 2002
A fast-tracked paper on a possible new ovarian cancer screening tool by Lance Liotta , M.D., Ph.D., National Cancer Institute (NCI), and Emanuel Petricoin, M.D., Food and Drug Administration (FDA), appeared electronically in The Lancet on February 7, 2002. BenchMarks interviewed the scientists about this new tool, which employs a technique called proteomics. The researchers talk about the tool, how it was developed, and its potential applicability to screening and treatment for ovarian and other cancers.
Proteomics: Research for the 21st Century
|
|
![](https://webarchive.library.unt.edu/eot2008/20090509235542im_/http://www.cancer.gov/images/spacer.gif) |
Related Article
Proteomics in Clinical Trials
Reported by Jennifer Michalowski
February 7, 2002
Proteomics - the study of the proteins inside cells - has made its way into cancer trials. New technologies that allow researchers to visualize thousands of proteins at the same time can reveal patterns that may have important clinical implications.
Proteomics in Clinical Trials
|
|
Attention, Reporters...
To receive BenchMarks and the news updates as soon as they are posted to the
Web, join the NCI News distribution list.
Sign up here! |
|
|
|
|
![](https://webarchive.library.unt.edu/eot2008/20090509235542im_/http://www.cancer.gov/images/spacer.gif) |